Table 1 Clinical characteristics, thrombotic events and outcomes of patients with SARS-CoV-2 and non-CoV-2 respiratory viruses.
SARS-CoV-2 (n = 182) | Non-CoV-2 respiratory viruses (n = 165) | P values | |
|---|---|---|---|
Demographics | |||
Age, Median (IQR) | 37 (30.51) | 35 (29.51) | 0.122 |
Gender—no.(%) | < 0.001 | ||
Male | 133 (73.1) | 87 (52.7) | |
Female | 49 (26.9) | 78 (47.3) | |
Race—no.(%) | < 0.001 | ||
Chinese | 63 (34.6) | 74 (44.8) | |
Malay | 6 (3.3) | 31 (18.8) | |
Indian | 81 (44.5) | 35 (21.2) | |
Others | 32 (17.6) | 25 (15.2) | |
Comorbidities—no.(%) | |||
Hypertension | 44 (24.2) | 28 (17.0) | 0.098 |
Hyperlipidemia | 15 (8.20) | 24 (18.50) | 0.063 |
Diabetes Mellitus | 10 (5.5) | 22 (13.3) | 0.012 |
Ischemic Heart Disease | 6 (3.30) | 13 (7.90) | 0.061 |
Prior stroke | 4 (2.20) | 5 (3.0) | 0.626 |
Renal disease | 1 (0.50) | 10 (6.10) | 0.003 |
Chronic lung disease | 18 (9.90) | 15 (9.10) | 0.800 |
Liver disease | 0 (0.00) | 3 (1.80) | 0.106 |
Active malignancy | 0 (0.00) | 3 (1.80) | 0.106 |
Charlson Comorbidity index | |||
Median (IQR) | 0 (0.1) | 0 (0.1) | 0.39 |
0–2 points | 167 (91.8) | 145 (87.9) | 0.231 |
≥ 3 points | 15 (8.2) | 20 (12.1) | |
Existing antithrombotic agents—no.(%) | |||
Antiplatelet | 8 (4.4) | 7 (4.2) | 1.0 |
Anticoagulation | 1 (0.5) | 1 (0.6) | 1.0 |
Thrombotic outcomes | |||
Arterial thrombosis—no.(%) | 2 (1.1) | 1 (0.6) | 1.0 |
Venous thrombosis—no.(%) | 0 | 0 | – |
Event/1000 patient days | 1.0 | 1.8 | 0.6308 |
Outcomes | |||
Required O2 supplementation—no.(%) | 20 (11.0) | 8 (4.8) | 0.035 |
HD—no.(%) | 2 (1.1) | 0 (0) | 0.500 |
ICU—no.(%) | 9 (4.9) | 2 (1.2) | 0.047 |
LOS in ICU, median (IQR) | 20 (9.27) | 5 (3.7) | 0.073 |
Total patient days in ICU | 160 | 10 | – |
LOS, Median (IQR) | 7.5 (6.13) | 3 (2.3) | < 0.001 |
Total patient days in hospital | 1979 | 554 | – |
Death—no.(%) | 2 (1.1) | 1 (0.6) | 1.0 |
